Crossmark

‘Atypical Ugi’ tetrazoles

Crossref DOI link: https://doi.org/10.1039/c9cc09194g

Published Online: 2020

Update policy: https://doi.org/10.1039/rsc_crossmark_policy

Authors

Abdelraheem, Eman M. M.

Goodwin, Imogen

Shaabani, Shabnam https://orcid.org/0000-0001-5546-7140
de Haan, Michel P.

Kurpiewska, Katarzyna

Kalinowska-Tłuścik, Justyna https://orcid.org/0000-0001-7714-1651
Dömling, Alexander https://orcid.org/0000-0002-9923-8873
Funding

Funding for this research was provided by:

Innovative Medicines Initiative (115489)

KWF Kankerbestrijding (10504)

Center for Scientific Review (2R01GM097082-05)

Seventh Framework Programme (FP7/2007-2013)

Horizon 2020 Framework Programme (675555, 665250)

European Regional Development Fund (POIG.02.01.00-12-023/08)
License Information

Version of Record valid from 2020-01-07
More Information

SIMILARITY CHECK

: This document is Similarity Check deposited

RELATED DATA

: Supplementary Information

: Crystal Structure Data

IDENTIFIERS

: Shabnam Shaabani (ORCID)

: Justyna Kalinowska-Tłuścik (ORCID)

: Alexander Dömling (ORCID)

PEER REVIEW METHOD

: Authors can choose between single-blind and double-blind peer review

PUBLICATION HISTORY

: Received 26 November 2019; Accepted 7 January 2020; Accepted Manuscript published 7 January 2020; Advance Article published 17 January 2020; Version of Record published 11 February 2020